Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.58 |
| ▸ | ALB | P02768 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27755117 | 0.88 | TTR (0.52) | TTRALBMEN1KMT2ACA2 | |
| SCHEMBL24193570 | 0.86 | TTR (0.83) | TTRALBMEN1KMT2ACA2 | |
| SCHEMBL29451006 | 0.84 | TTR (0.48) | TTRALBMEN1KMT2ACA2 | |
| SCHEMBL20973292 | 0.84 | TTR (0.72) | TTRALBMEN1KMT2ACA2 | |
| SCHEMBL12594013 | 0.84 | TTR (0.48) | TTRALBMEN1KMT2ACA2 | |
| SCHEMBL1733883 | 0.84 | KDM4E (0.54) | TTRALBMEN1KMT2ACA2 | |
| SCHEMBL1175832 | 0.84 | TTR (0.48) | TTRALBMEN1KMT2ACA2 | |
| SCHEMBL3659544 | 0.83 | TTR (0.52) | TTRALBMEN1KMT2ACA2 | |
| SCHEMBL30842649 | 0.83 | TTR (0.52) | TTRALBMEN1KMT2ACA2 | |
| SCHEMBL1175107 | 0.81 | EGFR (0.54) | TTRALBMEN1KMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 663 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010902-A | Carbonyl substituted pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof | 山东大学 | 2026-05-12 | — | — | CN | claimed |
| CN-119306712-A | Diaryl pyrimidine derivative containing condensed heterocycle and preparation method and application thereof | 山东大学 | 2025-01-14 | — | — | CN | claimed |
| CN-114853781-B | HIV-1 reverse transcriptase targeted covalent inhibitor and preparation method and application thereof | 山东大学苏州研究院 | 2023-09-08 | — | — | CN | claimed |
| CN-113720926-B | Method for detecting impurity content in itraconazole intermediate 1 | 浙江致新医药科技有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-114853781-A | HIV-1 reverse transcriptase targeted covalent inhibitor and preparation method and application thereof | 山东大学苏州研究院 | 2022-08-05 | — | — | CN | claimed |
| CN-113234027-B | 4, 6-bis (aryloxy) pyrimidine derivative and synthesis method and application thereof | 山东大学 | 2022-06-03 | — | — | CN | claimed |
| CN-112028836-B | Diarylpyrimidine derivative containing six-membered nitrogen heterocycle and preparation method and application thereof | 山东大学 | 2021-12-07 | — | — | CN | claimed |
| CN-113720926-A | Method for detecting impurity content in etravirine intermediate 1 | 浙江致新医药科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-113651799-A | Six-membered non-aromatic ring-containing diaryl pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof | 山东大学 | 2021-11-16 | — | — | CN | claimed |
| CN-111187222-B | Substituted pyrimidine derivative and preparation method and application thereof | 山东大学 | 2021-09-24 | — | — | CN | claimed |
| US-20130035485-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF ETRAVIRINE AND INTERMEDIATES THEREOF | KRIZMANIC IRENA (HR) | 2013-02-07 | — | — | US | claimed |
| WO-2012170647-A1 | PROCESS FOR THE PREPARATION OF ETRAVIRINE AND INTERMEDIATES IN THE SYNTHESIS THEREOF | ASSIA CHEMICAL INDUSTRIEW LTD. (IL) | 2012-12-13 | — | — | WO | claimed |
| WO-2012147104-A1 | NOVEL PROCESS FOR THE PREPARATION OF ETRAVIRINE | MYLAN LABORATORIES LTD (IN) | 2012-11-01 | — | — | WO | claimed |
| US-8153790-B2 | Process for the preparation and purification of etravirine and intermediates thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-04-10 | — | — | US | claimed |
| WO-2012001695-A1 | A PROCESS FOR ETRA VIRINE INTERMEDIATE AND POLYMORPHS OF ETRAVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2012-01-05 | — | — | WO | claimed |
| US-20110275812-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF ETRAVIRINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-11-10 | — | — | US | claimed |
| US-20110196156-A1 | PROCESS FOR SYNTHESIS OF DIARYLPYRIMIDINE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | GURJAR MUKUND KESHAV | 2011-08-11 | — | — | US | claimed |
| EP-2342186-A2 | PROCESS FOR SYNTHESIS OF DIARYLPYRIMIDINE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | Emcure Pharmaceuticals Limited (IN) | 2011-07-13 | — | — | EP | claimed |
| WO-2011017079-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF ETRAVIRINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-02-10 | — | — | WO | claimed |
| WO-2010150279-A2 | PROCESS FOR SYNTHESIS OF DIARYLPYRIMIDINE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | EMCURE PHARMACEUTICALS LIMITED (IN) | 2010-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275812-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF ETRAVIRINE AND INTERMEDIATES THEREOF | ALKBH1, ALKBH5, ALKBH3 | TTR 2632/4885ALB 3383/4885MEN1 4558/4885 |
| US-20130035485-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF ETRAVIRINE AND INTERMEDIATES THEREOF | ALKBH5, ALKBH1, ELOB | TTR 2115/4885ALB 3952/4885MEN1 4461/4885 |
| US-20110196156-A1 | PROCESS FOR SYNTHESIS OF DIARYLPYRIMIDINE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | TYMP, DPYD, POLR2H | TTR 1442/4885ALB 3979/4885MEN1 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.